NVNO NVNO
Company Profile ↓Company Overview
NVNO (NVNO) is a publicly traded company listed on with a market capitalization of $7.26M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -93.47% |
| 6 Months: | +8.21% |
| 3 Months: | +6.65% |
| 1 Month: | +0.45% |
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.20 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 93.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.80K | 27.88K | 31.07K | 83.36K | 41.66K | 31.24K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 38.80K | -105.06K | - | 83.36K | 41.66K | 31.24K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.05M | 4.88M | 4.01M | 4.06M | 3.80M |
| Operating Income | -1.23M | -1.81M | -1.46M | -3.11M | -1.49M | -1.58M | -1.96M | -1.83M | -1.51M | -1.55M | -1.92M | -2.81M | -2.39M | -2.71M | -5.33M | -6.99M | -6.15M | -6.80M | -6.81M | -5.35M | -5.50M | -5.45M | -6.17M | - | -7.05M | -4.88M | -4.01M | -4.06M | -3.80M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.92M | -4.76M | -3.90M | -3.94M | -3.77M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.69M | -4.54M | -3.74M | -3.85M | -3.60M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.25M | -2.25M | -4.75M | -5.05M | -1.47M | -1.57M | -1.95M | -1.81M | -1.16M | -1.63M | -1.97M | -2.77M | -2.38M | -2.39M | -5.33M | -7.06M | -6.10M | -6.39M | -6.47M | -5.00M | -4.99M | -4.96M | -5.64M | - | -6.69M | -4.54M | -3.74M | -3.85M | -3.60M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.63 | -0.54 | -0.57 | -0.58 | -0.45 | -0.31 | -0.31 | -0.35 | -7.75 | -11.52 | -8.05 | - | -5.89 | -5.37 |
| R&D Expense | 184.92K | 43.07K | 240.49K | 280.42K | 424.60K | 313.01K | 428.31K | 676.97K | 510.62K | 706.17K | 758.20K | 1.63M | 1.09M | 1.23M | 1.55M | 3.07M | 2.49M | 3.60M | 4.21M | 2.80M | 3.05M | 2.83M | 2.86M | 2.56M | 2.89M | 2.58M | - | 2.11M | 2.08M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 422.11K | 186.55K | 31.24K | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 2.45K | 186.55K | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 24.93M | 25.24M | 23.83M | 20.90M |
| Operating Income | -6.10M | -7.85M | -7.68M | -9.14M | - | -24.93M | -25.24M | -23.83M | -20.90M |
| EBITDA | - | - | - | - | - | -24.41M | -24.69M | -23.30M | -20.41M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | -24.67M | -23.52M | -21.82M | -19.47M |
| Tax Provision | - | - | - | - | - | - | - | - | - |
| Net Income | -7.79M | -13.04M | -7.63M | -9.14M | - | -24.67M | -23.52M | -21.82M | -19.47M |
| Diluted EPS | - | - | - | - | - | -77.00 | -66.85 | -44.53 | -33.06 |
| R&D Expense | 649.74K | 1.24M | 2.21M | 4.25M | 5.73M | 9.91M | 13.58M | 12.25M | 9.98M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.21M | 3.56M | 3.43M | 10.54M | - | 41.66M | 48.63M | 44.95M | 29.56M |
| Current Assets | - | - | - | - | - | - | 39.44M | 46.92M | 43.73M | 28.83M |
| Cash & Equivalents | 56.51K | 77.69K | 2.74M | 1.31M | 9.33M | - | 4.55M | 3.62M | 1.75M | 3.06M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 8.17M | 1.52M | 2.44M | 3.44M | - | 2.93M | 2.44M | 2.79M | 2.43M |
| Current Liabilities | - | - | 1.52M | 1.88M | 3.19M | - | 1.53M | 1.37M | 2.10M | 2.12M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | 1.72M | 1.40M | 1.06M | 700.00K |
| Total Equity | -4.22M | -11.13M | 2.04M | 989.94K | 7.10M | - | 38.73M | 46.20M | 42.16M | 27.13M |
| Shares Outstanding | - | - | - | - | - | - | 270.63K | 380.49K | 501.03K | 656.00K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.20M | -6.36M | -5.90M | -7.68M | - | -15.62M | -18.86M | -16.84M | -15.57M |
| Investing Cash Flow | 165.31K | -12.42K | -363.89K | -180.29K | - | -34.55M | -7.87M | 1.33M | 15.86M |
| Financing Cash Flow | 4.06M | 9.03M | 5.64M | 15.07M | - | 0 | 25.79M | 13.64M | 1.02M |
| Capital Expenditure | -10.94K | -12.42K | -363.89K | -180.29K | - | -115.00K | -33.00K | -37.00K | -5.00K |
| Free Cash Flow | -4.21M | -6.37M | -6.26M | -7.86M | - | -15.73M | -18.89M | -16.88M | -15.57M |
| Net Change in Cash | - | - | - | - | - | -50.17M | -935.00K | -1.87M | 1.31M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.6% | 100.0% | - | - | - | - | - | - | - |
| Operating Margin % | -1,445.9% | -4,210.5% | -24,566.5% | - | - | - | - | - | - |
| Net Margin % | -1,845.8% | -6,991.5% | -24,406.7% | - | - | - | - | - | - |
| ROE % | 70.0% | -640.5% | -770.3% | -128.7% | - | -63.7% | -50.9% | -51.8% | -71.8% |
| ROCE % | - | -385.7% | -492.7% | -124.3% | - | -62.1% | -53.4% | -55.6% | -76.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NVNO
enVVeno Study Projects About 2.2 Fewer Venous Ulcers Per Patient - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOVlZxaldFQnNMTXp1Ni1IWmhkRVNvd3Y1Q2tGMFJ5RU5qTDFuUlhMNmQ4bUNoaldVcDdVM0hQdkxqQ1NyMWtGcDVaRjZUOThCWTNoTVpvRlpjZTdUWXlMMHl3MFdsV3JRM0QwT2VYQnNTZ3hmQkdFQWxZRi1sanJCU2lQUzJxcHJxWkhBNl…
enVVe Venous Valve Trial Expected to Enroll About 230 Patients - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQdUo2aUNyU3BOc1p4cWM4ZWdFRUZRbi1RTDVUZHFEeG1lbkRGVndLRHF0OGJNMG5BcnRPUmNvUUo5dGhzODg5TW1wVGZvX1dISkdNblppTUxXRUdpZENIaExGdjhVbUx0XzZkNVVNZWJBcUZ2QVFMU01ZamFHR3RIOFZqcGZSV092MEY0dj…
enVVeno Medical Announces Reverse Stock Split - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxObGVub0hmNm1UenF1enAxRzY1NldoZF8zRjFrclRwNnFNY2REaGhSQ3YtNG0ySlY0OExFQWt2c1BleFdwZXZlXzFJTnNrNjJrMFpOdUdFb3RoTzJsa0JqNTNZZEh5Wlg2TkRDQzc2LWpzeTRoX3dMSDJNWHRBb0N1V0t3a3EzVFNCbFVVND…
NVNO|enVVeno Medical Corp|Price:10.690|Chg%:+0.090 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1rVXBDeERVN01BLUpkMER1cVpRMG1pX2lsbGNaaGh3dGJHN2paSUdtUWtYUWd4Rng1MUhKeGh4RUtFUERWblYtSWJWM2FwNXctLUxPMkFtSFZxcjk0eGg5LWExejZtbjZwY0RDOXhB?oc=5" target="_blank">NVNO|enVVeno Medica…
enVVeno Medical (NVNO) Declines as Stock Faces Key Support Test - Statistical Arbitrage - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOMTZWZS03X1Y5Q3lQYVJIZ1dCa1l5aEN4bkxicDVGVnVKc0RwSTFIT2VZUXhLVXNRY1JUSXQ0WGo4YjhHNU9oS1RWaTNaN0tGOVFBblk2ZDE4cGJjTWxSYWdkanhhZmdzWlhFUmtxUW9ob3FzNHU4NEFDOTdUVl9HZjROVzl1WDFMcXJseH…
AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1uLUlEYTYtcjZqVEZMMEM0emkxOU55WG1KNHFpS0x0ZV8xeVpJNXdmMlN6NXRKTW9LeGs5OFBJay1Bb3hwNWc?oc=5" target="_blank">AI Investing Insights - Official Homepage - Intellectia AI™</a> &nb…
NVNO — Frequently Asked Questions
What is the current share price of NVNO?
As of 2026-08-05 17:25 PDT, NVNO trades at $11.07 on NASDAQ/NYSE. Its 52-week range is $8.67 to $174.82.
What is the market capitalisation of NVNO?
NVNO has a market capitalisation of $7.26M on NASDAQ/NYSE.
What is the P/E ratio of NVNO?
NVNO trades at a trailing price-to-earnings (P/E) ratio of -0.33. Its price-to-book (P/B) ratio is 0.27.
What is the return on equity (ROE) of NVNO?
NVNO has a return on equity (ROE) of -71.77%. Its return on capital employed (ROCE) is -76.16%.
Is NVNO a good stock to buy?
This page provides a data-driven analysis of NVNO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.